"Patience is a Super Power" - "The Money is in the waiting"
Showing posts with label Smallcaps. Show all posts
Showing posts with label Smallcaps. Show all posts

Friday, March 27, 2026

A powerful setup for exponential growth from combining two of Canada's smallcap stocks (PNG and FLT)

 


structured, investor-grade case for combining both Kraken Robotics (TSXV: PNG) and Volatus Aerospace (TSXV: FLT) into a portfolio


 



👉 dual-use (commercial + defense) technologies leveraged into a historic NATO/Canada/U.S. defense supercycle.

(Ed Note: Disclosure - We are long both stocks and accumulating at these exceptionally low levels)


🧭 1. Macro Tailwind: A Once-in-Generation Defense Supercycle

Yesterday

Key facts (this is the foundation of this thesis):

  • NATO + Canada defense spending +20% YoY in 2025
  • Canada now at ~$63.4B annually (2% GDP) and rising
  • NATO targeting 5% of GDP by 2035 (massive structural shift)
  • Canada planning:
    • +85% defense R&D
    • +240% defense industry revenues
    • Domestic procurement shift (less reliance on U.S.)
  • Global defense spending heading toward $2.6 trillion annually

What this really means (investment lens):

This is not cyclical. It is:

  • A multi-decade reindustrialization of defense
  • A shift toward autonomous systems, AI, and unmanned warfare
  • A push for domestic suppliers (Canada/EU)

👉 This is exactly where Kraken + Volatus sit.


⚓ 2. Kraken Robotics — “Underwater AI + Robotics = Naval Force Multiplier”

📡 Core Technology Advantage

Kraken builds:

  • Synthetic aperture sonar (SAS)
  • Underwater drones (AUV/ROV systems)
  • Subsea batteries (critical for autonomy)
  • Ocean mapping + intelligence systems

These are used for:

  • Mine detection
  • Submarine tracking
  • Infrastructure protection (pipelines, cables)
  • Arctic surveillance

Why this matters:

Traditional naval power:

  • $billions per ship
  • decades to deploy

Kraken systems:

  • Deploy in <1 year
  • Cover more area at lower cost
  • Act as force multipliers

🚀 Growth Drivers (Next 24 Months)

1. NATO Naval Modernization + Arctic Security

  • Arctic is now a strategic battlefield
  • Canada explicitly prioritizing Arctic sovereignty
  • Underwater drones = essential for vast coastlines

👉 Kraken is almost perfectly aligned with this need.


2. Shift to Autonomous Naval Warfare

Modern naval doctrine:

  • Move from crew-heavy platforms → autonomous fleets
  • Subsea domain = least monitored, highest risk

Kraken’s niche:

  • “Eyes and ears of the ocean”

3. Export Leverage (Already Proven)

  • ~90% of revenue from international customers
  • Customers in 30+ countries

👉 This is critical:

  • Not dependent on slow Canadian procurement
  • Already integrated into NATO ecosystem

4. Dual-Use Flywheel

Commercial markets:

  • Offshore energy (oil, wind)
  • Subsea infrastructure inspection
  • Ocean mapping

Defense demand → scales manufacturing → lowers cost → boosts commercial margins


📈 Investment Thesis (Kraken)

Why exponential growth is plausible:

  • Small base + high-margin tech
  • Positioned at critical naval chokepoint
  • Direct exposure to:
    • NATO spending
    • Arctic expansion
    • subsea infrastructure security (huge emerging theme)

👉 If defense contracts accelerate, revenue can scale non-linearly


🚁 3. Volatus Aerospace — “Airspace Control + Drone Warfare Layer”

🛰️ Core Technology Stack

Volatus is not just drones — it’s a full-stack aerial intelligence platform:

  • UAV operations (inspection, surveillance, delivery)
  • Counter-drone systems (C-UAS)
  • AI-enabled airspace monitoring (SKYDRA platform)
  • Services + SaaS model emerging

  • ▶️ Volatus Aerospace enters a commercial contract to deploy remotely managed drones capable of delivering 100kg payloads to offshore wind turbines > > https://hubs.la/Q047vGMB0

🔥 Why Volatus is Strategically Important

1. The Drone War Era Is Here

Modern conflicts (Ukraine, Middle East):

  • Drones are now:
    • Surveillance tools
    • Strike weapons
    • Infrastructure threats

👉 Counter-drone = must-have capability

Market:

  • Counter-UAS expected >$20B by 2030

2. Defense + Civil Convergence

Volatus operates in:

  • Defense
  • Infrastructure inspection
  • Energy
  • Public safety

👉 Same platform → multiple revenue streams


3. Recurring Revenue Transition (Key Inflection)

  • SKYDRA = SaaS-based system
  • Moves business from:
    • Project-based → subscription model

👉 This is where valuation multiples expand.


4. Direct Tailwind from Canadian Policy

  • Canada explicitly pushing:
    • Domestic defense suppliers
    • Drone & surveillance capability
  • Volatus already positioned as:
    • Canadian-based operator with defense alignment


🚀 Growth Drivers (Next 24 Months)

1. Counter-Drone Demand Explosion

  • Airports, military bases, cities
  • NATO airspace protection mandates

2. NATO Infrastructure Protection

  • Pipelines, ports, energy grids
  • Requires:
    • Persistent aerial monitoring
    • Rapid deployment drones

3. Defense Contracts + Partnerships

  • Even small contracts → huge revenue impact (microcap effect)

4. SaaS + Platform Expansion

  • High-margin recurring revenue layer
  • Potential valuation re-rating event

📈 Investment Thesis (Volatus)

Why exponential growth is plausible:

  • Positioned at fastest-growing defense segment (drones)
  • Transitioning to software + recurring revenue
  • Benefiting from:
    • Defense spending
    • Civil infrastructure demand
    • AI-driven airspace control

👉 This is a classic small-cap asymmetry setup


⚖️ 4. Kraken vs Volatus — Complementary, Not Competing

CategoryKraken RoboticsVolatus Aerospace
DomainUnderwater (subsea)Airspace (UAV)
Core RoleNaval intelligenceAirspace control
Defense UseMine detection, surveillanceCounter-drone, ISR
Commercial UseEnergy, mappingInfrastructure, inspection
Revenue ModelHardware + servicesServices → SaaS shift
Strategic RoleOcean dominanceAirspace dominance

👉 Together they represent:
“Full-spectrum unmanned warfare exposure” (sea + air)


🧠 5. Why This Could Be an “Exponential Growth Window”

The Setup:

  1. Massive capital inflow (defense budgets)
  2. Structural shift to autonomy
  3. Domestic supplier preference (Canada/NATO)
  4. Small-cap companies with scalable tech

The Result:

  • Revenue growth is lumpy → then accelerates sharply
  • Contracts → backlog → scaling → margin expansion

⚠️ 6. Risks (It's Critical to Keep Grounded)

Kraken:

  • Procurement delays (Canada is slow)
  • Competition from large defense primes (Kongsberg, Thales)

Volatus:

  • Execution risk (microcap scaling)
  • Capital requirements / dilution
  • Fragmented drone market

🧭 7. Bottom-Line Investment View

Structuring this as I typically do:

🔵 Core Thesis:

“Autonomous warfare infrastructure is replacing traditional platforms — Kraken (sea) and Volatus (air) are early-stage suppliers to that shift.”

🟢 Portfolio Role:

  • Kraken = more proven, export-driven
  • Volatus = higher risk, higher upside (optionality)

⚡ Upside Scenario (2 years):

  • Kraken → steady contract scaling + margin expansion
  • Volatus → step-change growth if SaaS + defense contracts hit

🧩 Final Take

This is one of the rare setups where:

  • Macro (defense supercycle)
  • Technology (autonomy + AI)
  • Policy (domestic procurement)
  • Geography (Canada/NATO alignment)

👉 All point in the same direction

That’s exactly the environment where small-cap defense tech can go nonlinear.

Recent News:

Volatus Aerospace Reports Fiscal Year 2025 Financial Results

, from 8:30AM ET on Tuesday Mar 31, 2026 by Dow Jones

8:30AM ET on Tuesday Mar 31, 2026 by Dow Jones

   -- Revenue Growth of 26% year-over-year 
 
   -- Defence Equipment revenues more than 2x from 2024 
 
   -- Total Assets of C$92M+, up 60% year-over-year 
 
   -- Europe & UK revenue grew 150%, driven by NATO-aligned defence business 
 
   -- Current cash balance of C$41M 
 
   -- Secured a NATO defence contract valued at up to C$9M in Dec 2025 
 
   -- Establishment of the Volatus Innovation & Drone Manufacturing Facility in 
      Mirabel, QC 

Kraken Robotics is in the right place, at the right time, with the right technology for eager buyers!

Friday, June 20, 2025

We've been collecting these smallcap biotech and healthcare stocks this year! Here's why!

 


Small-Cap Biotech & Healthcare Stocks Poised for Growth

📈 Sector Outlook: Why Biotech + AI = Exponential Growth

Biotech is entering a new era where artificial intelligence (AI), synthetic biology, and precision medicine converge. Key drivers for exponential growth include:

  • AI-driven drug discovery is slashing R&D time and cost (e.g., Recursion, Insilico).

  • Personalized medicine via genomics and CRISPR is expanding.

  • RNA & gene editing breakthroughs are unlocking treatments for previously untreatable diseases.

  • M&A potential is strong as big pharma looks to restock pipelines.

  • Regulatory tailwinds (e.g., accelerated FDA pathways, Orphan Drug incentives).


🔬 Company-by-Company Analysis

1. CRISPR Therapeutics (CRSP)

  • Focus: Gene editing, CRISPR-Cas9-based therapies

  • Tech: Co-developed first-ever CRISPR therapy approved (Casgevy for sickle cell)

  • Poised for Growth? ✅ Yes — Revenue from Casgevy + pipeline in diabetes and oncology. Likely M&A target or licensing machine.

2. Editas Medicine (EDIT)

  • Focus: In vivo gene editing (eye diseases, blood disorders)

  • Tech: Proprietary CRISPR platform, EDIT-301 (sickle cell/beta thalassemia)

  • Poised for Growth? 🔄 Moderate — Tech is strong, but lags CRSP in execution. AI-driven targeting tools could boost efficiency.

3. Beam Therapeutics (BEAM)

  • Focus: Base editing (next-gen CRISPR)

  • Tech: Allows precise gene correction without cutting DNA. BEAM-302 (alpha-1 antitrypsin deficiency)

  • Poised for Growth? ✅ Yes — Highly differentiated platform. Strong IP. Potential to leapfrog CRSP in safety profile.

4. Phathom Pharmaceuticals (PHAT)

  • Focus: GI disorders (acid-related diseases)

  • Tech: Vonoprazan, a novel potassium-competitive acid blocker

  • Poised for Growth? 🔄 Moderate — Already commercialized (Voquezna). Market penetration will determine upside.

5. Arcturus Therapeutics (ARCT)

  • Focus: mRNA therapies and vaccines

  • Tech: LUNAR® platform for low-dose, long-acting delivery

  • Poised for Growth? ✅ Yes — RSV, COVID, and rare liver disease vaccines. Undervalued vs. mRNA peers. AI-driven formulation optimization could accelerate pipeline.

6. Cabaletta Bio (CABA)

  • Focus: Autoimmune diseases (e.g., myasthenia gravis)

  • Tech: Chimeric AutoAntibody Receptor (CAAR) T-cells – first of its kind

  • Poised for Growth? ✅ Yes — Positive early trials, huge TAM, and a first-mover in autoimmune cell therapy.

7. Intellia Therapeutics (NTLA)

  • Focus: In vivo and ex vivo gene editing

  • Tech: In vivo gene editing in humans (NTLA-2001 for ATTR amyloidosis)

  • Poised for Growth? ✅ Yes — First-ever systemic in vivo CRISPR data. Large pipeline. Strategic Regeneron partnership.

8. Recursion Pharmaceuticals (RXRX)

  • Focus: AI-first drug discovery

  • Tech: Massive phenomics + deep learning platform

  • Poised for Growth? ✅ Yes — Strong NVIDIA, Bayer, Roche partnerships. 

  • Best positioned for exponential AI compounding effect.

9. Viking Therapeutics (VKTX)

  • Focus: Obesity, NASH, and metabolic disorders

  • Tech: Dual GLP-1/GIP receptor agonists, thyroid receptor agonists

  • Poised for Growth? ✅ Yes — Strong data vs. Lilly/ Novo. Potential M&A. 

  • Obesity is a trillion-dollar market.

10. WELL Health Technologies (WELL.TO)

  • Focus: Telehealth, digital healthcare infrastructure

  • Tech: Clinic & EMR consolidation + AI for practice optimization

  • Poised for Growth? ✅ Yes (Canada-specific) — Expanding across North America, strong cash flow, undervalued relative to U.S. digital health plays.

11. Immix Biopharma (IMMX)

  • Focus: Rare cancers and immuno-oncology

  • Tech: TME Normalization technology + Cell therapy (NXC-201)

  • Poised for Growth? ✅ Yes (Speculative) — CAR-T for AL amyloidosis is unique. Watch for FDA designations and trial readouts.


📊 Summary Table

TickerAreaGrowth PotentialCatalyst/Edge
CRSPGene Editing✅ StrongFirst CRISPR drug, deep pipeline
EDITGene Editing🔄 ModerateSolid tech, trailing execution
BEAMBase Editing✅ StrongPrecise, safer CRISPR 2.0
PHATGI/Acid Disorders🔄 ModerateNovel PPI, already on market
ARCTmRNA✅ StrongUndervalued, strong delivery platform
CABAAutoimmune Cell Tx✅ StrongFirst-mover, unique platform
NTLAIn vivo Gene Editing✅ StrongFirst in vivo CRISPR, strategic alliances
RXRXAI Drug Discovery✅ StrongAI-native, huge data moat
VKTXObesity/Metabolic✅ StrongGLP-1 space challenger
WELL.TODigital Health✅ Strong (CAN)Telehealth + consolidation + AI use
IMMXImmuno-oncology✅ High-risk/rewardNiche CAR-T, unique approach

🤖 How AI Enhances the Sector

AI is supercharging the biotech cycle in 5 key ways:

  1. Faster drug discovery: Modeling thousands of compounds in silico (e.g., RXRX, Insilico).

  2. Target identification: AI finds patterns in genomics/proteomics faster than humans.

  3. Clinical trial optimization: Patient stratification and predictive analytics.

  4. AI-designed molecules: Using generative AI to create new molecules (see NVIDIA-RXRX).

  5. Operational efficiency: From R&D to supply chain (e.g., WELL.TO automating clinics).


💡 Conclusion

This portfolio is well-positioned at the intersection of biotech innovation and AI acceleration. Many of your holdings (BEAM, RXRX, CABA, NTLA, VKTX) sit on the edge of potential inflection points. Risk is inherent in small-cap biotech, but the upside is exponential—especially as AI flattens the cost/time curve in drug development and diagnostics.

Here is a custom portfolio weighting recommendation for this biotech and healthcare portfolio, based on a blend of:

  • Near-term catalysts (FDA milestones, partnerships)

  • Long-term technology potential

  • AI integration

  • M&A potential

  • Risk-adjusted return profile


🧬 Portfolio Weighting (Total = 100%)

TickerWeightRationale
VKTX12%Lead obesity drug candidate w/ compelling data. Near-term Phase 3, strong M&A interest. High TAM.
CRSP12%First-to-market CRISPR approval, expanding pipeline, JV with Vertex gives strong floor.
RXRX12%AI-native. Deep partnerships (NVIDIA, Roche). Exponential AI effect likely.
NTLA10%First in vivo gene editing success. ATTR and broader pipeline. Regeneron relationship key.
BEAM12%Next-gen base editing. Safer CRISPR could leapfrog CRSP/NTLA. Platform play.
(up from 10%)
CABA10%Unique CAAR-T for autoimmunity. Early positive signals. First-mover with high optionality.
ARCT8%Undervalued vs. peers. Solid RNA delivery. Good mRNA pipeline outside COVID.
WELL.TO8%Cash-generating digital health consolidator. AI use growing in clinics. Canada-focused hedge.
IMMX6%High risk/reward CAR-T play in amyloidosis. FDA designations would be a catalyst.
EDIT5%Still early, lagging CRSP/NTLA. Execution risk, but novel platform. Optionality remains.
PHAT5%Revenue-generating now. Acid drug space not exponential, but cash flow can support R&D.

📊 Allocation Summary

  • High conviction (36%): VKTX, RXRX, CRSP, BEAM

  • Platform/Tech optionality (30%): NTLA, BEAM(2) CABA

  • Mid-risk, undervalued (24%): ARCT, WELL.TO, IMMX

  • Lower conviction/slow execution (10%): EDIT, PHAT


🔄 Suggested Strategy

  • Rebalance quarterly based on trial results and FDA news.

  • Use trailing stops on IMMX/EDIT to manage downside.

  • Double-down on RXRX/VKTX if large-cap pharma partnerships or M&A rumors intensify.

  • Takeover Target Rankings (Highest Likelihood First)

    1. Viking Therapeutics (VKTX)

    • Why? Lead obesity drug (GLP-1/GIP agonist) shows best-in-class potential vs. Lilly/Novo.

    • Who might buy?

      • Pfizer – Failed in GLP-1; needs a strong obesity entry.

      • Amgen – Also pivoting to obesity; could bolt on VKTX.

      • GSK – Lacks obesity/metabolic pipeline, looking to catch up.


    2. Cabaletta Bio (CABA)

    • Why? Unique CAAR-T cell therapy for autoimmune diseases. First mover. Fits immunology + cell therapy goals.

    • Who might buy?

      • Johnson & Johnson – Strong in immunology, buying into cell therapy.

      • Roche – Building autoimmune pipeline via Genentech.

      • Bristol Myers Squibb – Needs pipeline renewal, big cell therapy presence.


    3. Beam Therapeutics (BEAM)

    • Why? Proprietary base editing platform. Safer gene editing = attractive platform licensing or acquisition.

    • Who might buy?

      • Pfizer – Strong interest in next-gen gene editing.

      • Novartis – Genomic medicine investment fits BEAM tech.

      • Vertex – Deep in CRISPR, may hedge against dependence on CRSP.


    4. Intellia Therapeutics (NTLA)

    • Why? First to show systemic in vivo CRISPR edits. Regeneron partnership is a natural acquisition bridge.

    • Who might buy?

      • Regeneron – Already invested and partnered; would consolidate pipeline.

      • Sanofi – Gene therapy interest, looking to strengthen rare disease footprint.

      • Biogen – Rebuilding pipeline, interested in neuro/rare disease applications.


    5. Recursion Pharmaceuticals (RXRX)

    • Why? AI-native platform + massive phenomics database. Attractive for big pharma needing AI capability.

    • Who might buy?

      • Roche – Existing multi-program partnership.

      • Bayer – Deep AI collaboration; possible acquirer if results mature.

      • Merck – Lagging in AI drug discovery, could accelerate with RXRX’s tech.


    6. Arcturus Therapeutics (ARCT)

    • Why? mRNA delivery platform with long-acting advantage. LUNAR tech + RSV program is attractive.

    • Who might buy?

      • Sanofi – Recently bought mRNA players; interested in vaccines.

      • GSK – Focused on respiratory + mRNA.

      • Moderna – Could consolidate rival tech.


    7. CRISPR Therapeutics (CRSP)

    • Why? Already partnered with Vertex on Casgevy. Revenue coming in, but less likely to be bought due to high market cap.

    • Who might buy?

      • Vertex – Possible full acquisition to internalize CRISPR platform.

      • Pfizer – May bid if it wants deeper entry into gene editing.


    8. Immix Biopharma (IMMX)

    • Why? Niche CAR-T for amyloidosis + solid tumor microenvironment platform. High risk/reward.

    • Who might buy?

      • Bristol Myers Squibb – Deep CAR-T presence.

      • Legend Biotech – Could bolt on if data matures.

      • Takeda – Active in rare cancers and blood disorders.


    9. Editas Medicine (EDIT)

    • Why? Unique CRISPR IP, but lags in execution. May be picked up for tech/IP rather than pipeline.

    • Who might buy?

      • Editas’ own licensors (e.g., Broad/Harvard groups) could push for a sale.

      • Novartis – Possible platform bolter.

      • Smaller biotech consolidators (e.g., Beam or Arbor) could scoop the IP.


    10. Phathom Pharmaceuticals (PHAT)

    • Why? Already commercial, but niche acid blocker market. More of a bolt-on than a strategic buy.

    • Who might buy?

      • Takeda – Long history in GI disorders.

      • AbbVie – GI presence via Humira replacement efforts.


    11. WELL Health Technologies (WELL.TO)

    • Why? Telehealth/EMR company with cash flow but mostly Canadian. Acquisition unlikely by global pharma.

    • Who might buy?

      • Telus Health, Shopify Health, or U.S. PE firms rather than big pharma.


    🧬 Summary: Most Likely Pharma Suitors

    TargetBig Pharma Suitor(s)Rationale
    VKTXPfizer, Amgen, GSKObesity war heating up
    CABAJ&J, BMS, RocheAutoimmune + cell therapy convergence
    BEAMPfizer, Novartis, VertexPlatform potential, CRISPR 2.0
    NTLARegeneron, SanofiATTR and systemic gene editing
    RXRXRoche, Bayer, MerckAI-native platform, partnerships
    ARCTSanofi, GSK, ModernaLong-acting mRNA delivery
    CRSPVertex, PfizerDeep CRISPR pipeline, existing ties
    IMMXBMS, Takeda, LegendNiche oncology, CAR-T play
    EDITNovartis, IP playersIP/license value
    PHATTakeda, AbbVieGI pipeline bolt-on
    WELL.TOTelus, PE firms


Updates

 July 16th 2025

We have added Phage Therapeutics, PHGE to this list with a small position!


July 18th

Added Butterfly Networks - BFLY

Related articles:

We added to our position in Viking Therapeutics last week as the summer of Bio Tech M&A moves forward!